



V I S T A

THE VISTA STUDY

For adults 18 to 55 years of age, with relapsing-remitting multiple sclerosis

Dear Friend,

As someone living with relapsing-remitting multiple sclerosis (RRMS), you may be interested in learning about the **VISTA Study**, a clinical research trial investigating a new therapy to help treat RRMS.

WHAT IS THE PURPOSE OF THE VISTA STUDY?

The study hopes to provide us with a better understanding of the safety profile of the investigational therapy PIPE-307. This study will also allow us to learn more about how PIPE-307 moves into, through, and out of the body.

WHAT HAPPENS DURING THE STUDY?

The study has three parts – screening, treatment, and follow-up. Participants will be in the study for up to 20 weeks and there will be 6 study visits.

1	2	3
SCREENING	TREATMENT	FOLLOW-UP
1 visit	4 visits	1 visit
3 weeks*	12 weeks	4 weeks after last study dose

*Minimum period of 1 week between screening and treatment periods.

WHAT IS THE TREATMENT?

The drug being studied is called PIPE-307. You will take the study drug in tablet form by mouth for 12 weeks at home. On the days of study visits, you will take the study drug while at the clinic.

You will be assigned by chance to one of three treatment groups:

- 10 mg PIPE-307
- 20 mg PIPE-307
- Placebo (no active ingredient)

If you would like to learn more about the VISTA Study, please contact:

Emily or Madison at 480-210-8723.

